Obtenga las últimas noticias sobre las acciones de Viatris con actualizaciones sobre las tendencias del mercado, las finanzas y el análisis de Benzinga. Manténgase informado sobre el rendimiento de VTRS

Últimas noticias sobre

VIATRIS INC

Viatris

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

Viatris Inc

Dividends

Press Releases

Viatris Announces Quarterly Dividend

Earnings

Viatris Reports Second Quarter 2025 Results and Reiterates 2025 Financial Guidance

Viatris Announces Approval of First Generic Iron Sucrose Injection in the U.S.

Viatris Appoints Andrew Enrietti as Chief Administrative and Transformation Officer

Mapi Pharma Announces First Patient Recruited in Phase-I/II Study of Cariprazine Depot Once Monthly Injection

Viatris to Report Third Quarter 2025 Financial Results on November 6, 2025

Viatris Named to Forbes' Annual List of the World's Best Employers for the Fifth Year in a Row

Viatris to Participate in Upcoming Investor Conferences

Viatris Completes Acquisition of Aculys Pharma Including Exclusive Rights to Pitolisant in Japan and to Spydia® in Japan and Certain Other Markets in the Asia-Pacific Region

Locus Biosciences Enters Research Collaboration to Develop Precision Antibacterial Therapies for Ophthalmic Infections

VTRS

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Belite Bio, Inc - American Depositary Shares

Belite Bio

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Crinetics Pharmaceuticals, Inc. - Common Stock

Crinetics Pharmaceuticals

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Indivior

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Ligand Pharmaceuticals Incorporated - Common Stock

Ligand Pharmaceuticals

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Regencell Bioscience Holdings Limited - Ordinary Shares

Regencell Bioscience

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Takeda Pharmaceutical Co

Teva Pharmaceutical Industries Limited American Depositary Shares

Teva Pharmaceutical Indus

Zoetis

Truist Securities

Goldman Sachs

Jefferies

Piper Sandler

Barclays

Screenshot 2024-09-30 at 5.38.54 PM

Biotech

Movers & Shakers

General

COSM

Nestle Sponsored representing Registered Shares Series B

NSRGY

How Cosmos Health&#39;s Acquisition Of Almost 100-Year-Old Company, Adding To Capabilities Like Contract Manufacturing, Could Generate Over $10 Million In Annual Gross Profit

Comments

Viatris Noticias bursátiles

Noticias

Últimas noticias sobre

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL